HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional...

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Feb 28

PMID 36851682

Authors

Kunihiko Umekita

Yuki Hashikura

Akira Takaki

Masatoshi Kimura

Katsumi Kawano

Chihiro Iwao

Shunichi Miyauchi

Takeshi Kawaguchi

Motohiro Matsuda

Yayoi Hashiba

Toshihiko Hidaka

Affiliations

Soon will be listed here.

Abstract

The study aims to assess the usefulness of human T-cell leukemia virus type 1 (HTLV-1)-infected cell analysis using flow cytometry (HAS-Flow) as a monitoring method for adult T-cell leukemia (ATL) development in HTLV-1-positive patients with rheumatoid arthritis (RA) under treatment with antirheumatic therapies. A total of 13 HTLV-1-negative and 57 HTLV-1-positive RA patients participated in this study, which was used to collect clinical and laboratory data, including HAS-Flow and HTLV-1 proviral load (PVL), which were then compared between the two groups. CADM1 expression on CD4+ cells in peripheral blood (PB) was used to identify HTLV-1-infected cells. The population of CADM1+ CD4+ cells was significantly higher in HTLV-1-positive RA patients compared to HTLV-1-negative RA patients. The population of CADM1+ CD4+ cells was correlated with HTLV-1 PVL values. There were no antirheumatic therapies affecting both the expression of CADM1 on CD4+ cells and PVLs. Six HTLV-1-positive RA patients who indicated both high HTLV-1 PVL and a predominant pattern of CADM1+ CD7neg CD4+ cells in HAS-Flow can be classified as high-risk for ATL progression. HAS-Flow could be a useful method for monitoring high-risk HTLV-1-positive RA patients who are at risk of developing ATL during antirheumatic therapies.

Citing Articles

Antiviral immune response against HTLV-1 invalidates T-SPOT.TB results in patients with HTLV-1-positive rheumatic diseases.

Kimura M, Umekita K, Iwao C, Kawano K, Hashikura Y, Hashiba Y Front Immunol. 2024; 15:1480506.

PMID: 39534598 PMC: 11554456. DOI: 10.3389/fimmu.2024.1480506.

References

Kobayashi S, Watanabe E, Ishigaki T, Ohno N, Yuji K, Nakano K . Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci. 2015; 106(5):598-603. PMC: 4452161. DOI: 10.1111/cas.12639. View

Firouzi S, Farmanbar A, Nakai K, Iwanaga M, Uchimaru K, Utsunomiya A . Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. Blood Adv. 2018; 1(15):1195-1205. PMC: 5728319. DOI: 10.1182/bloodadvances.2017005900. View

Wada Y, Sato T, Hasegawa H, Matsudaira T, Nao N, Coler-Reilly A . RAISING is a high-performance method for identifying random transgene integration sites. Commun Biol. 2022; 5(1):535. PMC: 9163355. DOI: 10.1038/s42003-022-03467-w. View

Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N . The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005; 191(7):1140-7. DOI: 10.1086/428625. View

Sarkar B, Nishikata I, Nakahata S, Ichikawa T, Shiraga T, Saha H . Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-κB. Sci Rep. 2019; 9(1):3491. PMC: 6400899. DOI: 10.1038/s41598-019-39424-7. View

Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, GHOSH H . TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001; 27(4):427-30. DOI: 10.1038/86934. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Sepriano A, Kerschbaumer A, Smolen J, van der Heijde D, Dougados M, van Vollenhoven R . Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020; 79(6):760-770. DOI: 10.1136/annrheumdis-2019-216653. View

Anderson J, Zimmerman L, Caplan L, Michaud K . Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S14-36. DOI: 10.1002/acr.20621. View

10.

Smolen J, Landewe R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655. View

11.

Umekita K, Hashiba Y, Kariya Y, Kubo K, Miyauchi S, Aizawa A . The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. Mod Rheumatol. 2018; 29(5):795-801. DOI: 10.1080/14397595.2018.1519890. View

12.

Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K . CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014; 20(11):2851-61. DOI: 10.1158/1078-0432.CCR-13-3169. View

13.

Burmester G, Pope J . Novel treatment strategies in rheumatoid arthritis. Lancet. 2017; 389(10086):2338-2348. DOI: 10.1016/S0140-6736(17)31491-5. View

14.

Singh J, Saag K, Bridges Jr S, Akl E, Bannuru R, Sullivan M . 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015; 68(1):1-25. DOI: 10.1002/acr.22783. View

15.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

16.

Smolen J, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960-977. DOI: 10.1136/annrheumdis-2016-210715. View

17.

Sasaki H, Nishikata I, Shiraga T, Akamatsu E, Fukami T, Hidaka T . Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. 2004; 105(3):1204-13. DOI: 10.1182/blood-2004-03-1222. View

18.

Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K . Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia. 2012; 26(6):1238-46. DOI: 10.1038/leu.2011.379. View

19.

Satake M, Yamaguchi K, Tadokoro K . Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2011; 84(2):327-35. DOI: 10.1002/jmv.23181. View

20.

Arisaw K, Katamine S, Kamihira S, Kurokawa K, Sawada T, Soda M . A nested case-control study of risk factors for adult T-cell leukemia/lymphoma among human T-cell lymphotropic virus type-I carriers in Japan. Cancer Causes Control. 2002; 13(7):657-63. DOI: 10.1023/a:1019511224501. View